Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

NCT01319864 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT01319864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01319864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2011
Completion date
June 28, 2016
Enrollment
20 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia of ambiguous lineage, all, aml, relapsed/refractory all, relapsed/refractory aml, secondary aml/mds